Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP

Kate Kolaczinski, Toby Leslie, Iftikhar Ali, Naeem Durrani, Sue Lee, Marion Barends, Khalid Beshir, Rosalynn Ord, Rachel Hallett, Mark Rowland, Kate Kolaczinski, Toby Leslie, Iftikhar Ali, Naeem Durrani, Sue Lee, Marion Barends, Khalid Beshir, Rosalynn Ord, Rachel Hallett, Mark Rowland

Abstract

Introduction: Antimalarial resistance has led to a global policy of artemisinin-based combination therapy. Despite growing resistance chloroquine (CQ) remained until recently the official first-line treatment for falciparum malaria in Pakistan, with sulfadoxine-pyrimethamine (SP) second-line. Co-treatment with the gametocytocidal primaquine (PQ) is recommended for transmission control in South Asia. The relative effect of artesunate (AS) or primaquine, as partner drugs, on clinical outcomes and gametocyte carriage in this setting were unknown.

Methods: A single-blinded, randomized trial among Afghan refugees in Pakistan compared six treatment arms: CQ; CQ+(single-dose)PQ; CQ+(3 d)AS; SP; SP+(single-dose)PQ, and SP+(3 d)AS. The objectives were to compare treatment failure rates and effect on gametocyte carriage, of CQ or SP monotherapy against the respective combinations (PQ or AS). Outcomes included trophozoite and gametocyte clearance (read by light microscopy), and clinical and parasitological failure.

Findings: A total of 308 (87%) patients completed the trial. Failure rates by day 28 were: CQ 55/68 (81%); CQ+AS 19/67 (28%), SP 4/41 (9.8%), SP+AS 1/41 (2.4%). The addition of PQ to CQ or SP did not affect failure rates (CQ+PQ 49/67 (73%) failed; SP+PQ 5/33 (16%) failed). AS was superior to PQ at clearing gametocytes; gametocytes were seen on d7 in 85% of CQ, 40% of CQ+PQ, 21% of CQ+AS, 91% of SP, 76% of SP+PQ and 23% of SP+AS treated patients. PQ was more effective at clearing older gametocyte infections whereas AS was more effective at preventing emergence of mature gametocytes, except in cases that recrudesced.

Conclusions: CQ is no longer appropriate by itself or in combination. These findings influenced the replacement of CQ with SP+AS for first-line treatment of uncomplicated falciparum malaria in the WHO Eastern Mediterranean Region. The threat of SP resistance remains as SP monotherapy is still common. Three day AS was superior to single-dose PQ for reducing gametocyte carriage.

Trial registration: ClinicalTrials.gov NCT00959517.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
Figure 2. Kaplan Meier survival analysis showing…
Figure 2. Kaplan Meier survival analysis showing cumulative probability of failure in CQ treatment groups (A) and SP treatment groups (B).
Figure 3. Percentage of patients (+CI) carrying…
Figure 3. Percentage of patients (+CI) carrying gametocytes on specified days after treatment in CQ (A) and SP (B) treatment arms.
Figure 4. Geometric mean gametocyte density (+CI)…
Figure 4. Geometric mean gametocyte density (+CI) after treatment in chloroquine (A) and SP treatment arms (B).
Note the different scales on the Y-axis. Where the CI bars are absent, only 1 patient had gametocytes.

References

    1. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–334.
    1. Shah I, Rowland M, Mehmood P, Mujahid C, Razique F, et al. Chloroquine resistance in Pakistan and the upsurge of falciparum malaria in Pakistani and Afghan refugee populations. Ann Trop Med Parasitol. 1997;91:591–602.
    1. Rab MA, Freeman TW, Durrani N, De Poerck D, Rowland MW. Resistance of Plasmodium falciparum malaria to chloroquine is widespread in eastern Afghanistan. Ann Trop Med Parasitol. 2001;95:41–46.
    1. Khan MA, Smego RAJ, Razi ST, Beg A. Emerging drug resistance and guidelines for treatment of malaria. J Coll Physicians Surg Pak. 2004;14:319–324.
    1. Rowland M, Durrani N, Hewitt S, Sondorp E. Resistance of falciparum malaria to chloroquine and sulfadoxine-pyrimethamine in Afghan refugee settlements in western Pakistan: surveys by the general health services using a simplified in vivo test. Trop Med Int Health. 1997;2:1049–1056.
    1. Bloland PB, Ettling M, Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ. 2000;78:1378–1388.
    1. Nosten F, Ashley E. The detection and treatment of Plasmodium falciparum malaria: time for a change. J Postgrad Med. 2004;50:35–39.
    1. Ezard N, Nellepalli P, Asha AW. Sulfadoxine-pyrimethamine remains efficacious against uncomplicated Plasmodium falciparum malaria in north-eastern Afghanistan. Ann Trop Med Parasitol. 2004;98:85–88.
    1. Campbell P, Baruah S, Narain K, Rogers CC. A randomized trial comparing the efficacy of four treatment regimens for uncomplicated falciparum malaria in Assam state, India. Trans R Soc Trop Med Hyg. 2006;100:108–118.
    1. Reickmann KH, McNamara JV, Kass L, Powell RD. Gametocytocidal and sporontocidal effects of primaquine upon two strains of Plasmodium falciparum. Mil Med. 1969;134(10):802–19.
    1. Chomcharn Y, Surathin K, Bunnag D, Sucharit S, Harinasuta T. Effect of a single dose of primaquine on a Thai strain of Plasmodium falciparum. Southeast Asian J Trop Med Public Health. 1980;11:408–412.
    1. Kaneko A, Kamei K, Suzuki T, Ishii A, Siagian R, et al. Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health. 1989;20:351–359.
    1. Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, et al. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother. 2004;48:1329–1334.
    1. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10:673–681.
    1. Targett G, Drakeley C, Jawara M, Von Seidlein L, Coleman R, et al. Artesunate reduces but does not prevent post-treatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis. 2001;183:1254–1259.
    1. Von Seidlein L, Jawara M, Coleman R, Doherty T, Walraven G, et al. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. Trop Med Int Health. 2001;6:92–98.
    1. Chotivanich K, Sattabongkot J, Udomsangpetch R, Looareesuwan S, Day NP, et al. Transmission-blocking activities of quinine, primaquine, and artesunate. Antimicrob Agents Chemother. 2006;50:1927–1930.
    1. Sutherland CJ, Drakeley CJ, Obisike U, Coleman R, Jawara M, et al. The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure. Am J Trop Med Int Health. 2003;69:19–25.
    1. Nosten F, Van vugt M, Price R, Luxemburger C, Thwai KL, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000;365:297–302.
    1. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2005;2:e330.
    1. Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J. 2009;8(Suppl 1):S8.
    1. Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007;4:e309.
    1. O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, et al. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg. 2008;79:185–191.
    1. WHO Prevention and Control of Malaria Epidemics: Forcasting, preventions, early detection and control – From policy to practice. 2004. Report of an informal consultation. Geneva: World Health Organisation.
    1. Najera JA, Kouznetsov RL, Delacollete C. Malaria epidemics: Detection and Control, Forecasting and Prevention. Geneva: World Health Organisation; 1998.
    1. Shekalaghe SA, Bousema JT, Kunei KK, Lushino P, Masokoto A, et al. Submicroscopic Plasmodium falciparum gametocyte carriage is common in an area of low and seasonal transmission in Tanzania. Trop Med Int Health. 2007;12:547–553.
    1. Suleman M. Malaria in Afghan refugees in Pakistan. Trans R Soc Trop Med Hyg. 1988;82:44–47.
    1. Rowland M, Rab MA, Freeman T, Durrani N, Rehman N. Afghan refugees and the temporal and spatial distribution of malaria in Pakistan. Soc Sci Med. 2002;55:2061–2072.
    1. Leslie T, Kaur H, Mohammed N, Kolaczinski K, Ord R, et al. An epidemic of Plasmodium falciparum malaria in Afghan refugees in Pakistan involving substandard antimalarial drugs. Emerg Infect Dis. 2009;15:1753–1759.
    1. Rowland M, Durrani N, Hewitt S, Sondorp E. Resistance of falciparum malaria to chloroquine and sulfadoxine-pyrimethamine in Afghan refugee settlements in western Pakistan: surveys by the general health services using a simplified in vivo test. Trop Med Int Health. 1997;2:1049–1056.
    1. WHO. The use of antimalarial drugs. 2001. Report of a WHO informal consultation. (WHO/CDSRBM/200133). Geneva: World Health Organisation.
    1. Myint HY, Tipmanee P, Nosten F, Day NP, Pukrittayakamee S, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg. 2004;98:73–81.
    1. WHO. Basic malaria microscopy – 2nd edition. 2010. Part 1: Learner's guide - Part 2: Tutor's guide. World Health Organisation, Geneva, Switzerland.
    1. WHO. Practical Chemotherapy of Malaria. WHO Technical Report Series No. 805. Geneva: World Health Organisation; 1991.
    1. WHO. Monitoring Antimalarial Drug Resistance. 2002. Report of a WHO consultation. (WHO/CDS/RBM/200239). Geneva: World Health Organisation.
    1. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organisation; 2009.
    1. Shah NK, Dhillon GPS, Dash AP, Meshnick SR, Valecha N. Antimalarial drug resistance of Plasmodium falciparum in India: changes in time and space. Lancet. 2011;11:57–64.
    1. Brockman A, Paul RE, Anderson TJC, Hackford I, Phaiphun L, et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the north western border of Thailand. Am J Trop Med Hyg. 2000;60:14–21.
    1. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2007;51:991–997.
    1. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother. 2003;47:1347–1354.
    1. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565–568.
    1. Peterson DS, Milhous WK, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci U S A. 1990;87:3018–3022.
    1. WHO. 2004. Report of the Third Intercountry Meeting of National Malaria Control Managers, Lahore, Pakistan. (WHO-EM/MAL/297/E/0504/140). Geneva: World Health Organisation.
    1. Kolaczinski K, Durrani N, Rahim S, Rowland M. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. Trans R Soc Trop Med Hyg. 2007;101:1081–1087.
    1. Durrani N, Leslie T, Rahim S, Graham K, Ahmad F, et al. Efficacy of combination therapy with artesunate plus amodiaquine compared to monotherapy with chloroquine, amodiaquine or sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum in Afghanistan. Trop Med Int Health. 2005;10:521–529.
    1. Ghanchi NK, Ursing J, Beg MA, Veiga MI, Jafri S, et al. Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan. Malar J. 2011;10:18.
    1. Khatoon L, Baliraine FN, Bonizzoni M, Malik SA, Yan G. Prevalence of antimalarial drug resistance mutations in Plasmodium vivax and P. falciparum from a malaria-endemic area of Pakistan. Am J Trop Med Hyg. 2009;81:525–528.
    1. Fox E, Khaliq AA, Sarwar M, Strickland GT. Chloroquine-resistant Plasmodium falciparum: now in Pakistani Punjab. Lancet. 1985:1432–1434.
    1. Khaliq AA, Sarwar M, Fox E, Strickland ST. Chloroquine resistant Plasmodium falciparum in the Punjab. Pak J Med Res. 1985;24
    1. Dondorp AM, Nosten F, Poravuth Y. Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med. 2009;361:455–467.
    1. Robert V, Awono-Ambene HP, Le Hesran JY, Trape JF. Gametocytaemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg. 2000;62:210–216.
    1. International Artemisinin Study Group. Artesunate combinations for treatment of malaria: a meta-analysis. Lancet. 2004;363:9–17.
    1. Butcher GA. Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol. 1997;27:975–987.
    1. Wilairatana P, Tangpukdee N, Krudsood S. Long term primaquine administration to reduce Plasmodium falciparum gametocyte transmission in hypoendemic areas. Southeast Asian J Trop Med Public Health. 2010;41:1306–1311.
    1. Karl S, Gurarie D, Zimmerman PA, King CH, St Pierre TG, et al. A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One. 2011;6:e20805.
    1. Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis. 2009;200:1509–1517.
    1. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377–410.
    1. Beavogui AH, Djimde AA, Gregson A, Toure AM, Dao A, et al. Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int J Parasitol. 2010;40:1213–1220.
    1. Jansen FH. Effectiveness of ACTs in cases of resistance to partner drugs. Lancet Infect Dis. 2011;11:498–499.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅